Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.00166-25 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Tae Yeul Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Colistin, Anti-Bacterial Agents, Gram-Negative Bacteria, Carbapenems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute.
Abstract (Originalsprache)
We assessed the performance of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations and colistin in carbapenem-non-susceptible gram-negative isolates. A total of 425 clinical isolates, including Enterobacterales ( n = 242), Pseudomonas aeruginosa ( n = 97), and Acinetobacter baumannii ( n = 86), were tested using VITEK 2, with broth microdilution as the reference standard. Minimum inhibitory concentrations were interpreted according to Clinical and Laboratory Standards Institute breakpoints. The essential agreement (EA), categorical agreement (CA), very major error rate, and major error rate for VITEK 2 were 90.3%, 97.6%, 1.8%, and 2.5% for ceftazidime/avibactam; 81.5%, 89.0%, 7.0%, and 4.7% for ceftolozane/tazobactam; 96.5%, 90.9%, 3.4%, and 1.2% for imipenem/relebactam; and 94.6%, 93.0%, 15.8%, and 3.2% for meropenem/vaborbactam. For colistin, VITEK 2 demonstrated an EA of 89.2% and a CA of 85.4%. Our findings suggest that VITEK 2 has suboptimal performance for novel BL/BLI combinations in carbapenem-non-susceptible gram-negative isolates. Furthermore, despite changes to the colistin formulation used in the VITEK 2 card, it remains an unreliable method for detecting colistin resistance. IMPORTANCE Rapid and accurate antimicrobial susceptibility testing (AST) is essential for managing infections caused by multidrug-resistant gram-negative bacilli. This study evaluated the performance of the VITEK 2 AST-N439 card for susceptibility testing of novel BL/BLI combinations and colistin in carbapenem-non-susceptible gram-negative isolates. Our findings revealed significant limitations, including suboptimal performance for novel BL/BLI combinations and unreliable detection of colistin resistance, even with the updated formulation. These results underscore the need for cautious interpretation of VITEK 2 results and highlight the importance of optimizing its performance to enhance antibiotic decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea.
- Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Laboratory Medicine, Seoul Medical Center, Seoul, Republic of Korea.
- Department of Medical Device Management and Research, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
ORCID-Profile: Tae Yeul Kim, Jae-Hoon Ko, Hee Jae Huh, Nam Yong Lee
Förderung
- Korea Health Industry Development Institute
Zitieren
APA
Kim, T. Y., Baek, J. Y., Suh, E., Lee, J. K., Yu, H. J., Ko, J. H., Huh, H. J., & Lee, N. Y. (2025). Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00166-25
Vancouver
Kim TY, Baek JY, Suh E, Lee JK, Yu HJ, Ko JH, et al. Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00166-25
BibTeX
@article{Kim2025,
author = {Kim, Tae Yeul and Baek, Jin Yang and Suh, Eunsang and Lee, Jun-Ki and Yu, Hui-Jin and Ko, Jae-Hoon and Huh, Hee Jae and Lee, Nam Yong},
title = {Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.00166-25}
}
EUVIMED